Department of Hepatobiliary Surgery, Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China ; Second Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China.
PLoS One. 2013 Sep 26;8(9):e75559. doi: 10.1371/journal.pone.0075559. eCollection 2013.
Pancreatic cancer is one of the most troublesome malignancies with dismal prognosis. H. pylori has been recognized as a type I carcinogen. Several studies have evaluated the association between H. pylori infection and pancreatic cancer development, however, the conclusions are inconsistent.
Literature search was carried out in PubMed, EMBASE, Cochrane Library and CNKI databases to identify eligible researches. We performed overall meta-analysis of all studies included and subgroup analysis based on regional distribution. Quality of the studies (assessed by Newcastle-Ottawa quality assessment scale for case-control studies) and CagA+ strains of H. pylori were taken into consideration, and we conducted additional analyses including high-quality researches and those concerning CagA+ H. pylori respectively.
9 studies involving 3033 subjects (1083 pancreatic cancer cases, 1950 controls) were included. Summary OR and 95%CI of the overall meta-analysis of all included studies were 1.47 and 1.22-1.77, pooled data of the 4 high-quality studies were OR 1.28, 95%CI 1.01-1.63. OR of the 5 studies examined CagA+ strains was 1.42, corresponding 95%CI was 0.79 to 2.57. Summary estimates of subgroup analysis based on regional distribution are as follows, Europe group: OR 1.56, 95%CI 1.15-2.10; East Asia group: OR 2.01, 95%CI 1.33-3.02; North America group: OR 1.17, 95%CI 0.87-1.58. There was not obvious heterogeneity across the 9 studies. No publication bias was detected.
H. pylori infection is significantly, albeit weakly, associated with pancreatic cancer development. The association is prominent in Europe and East Asia, but not in North America. CagA+ H. pylori strains appear not to be associated with pancreatic cancer. However, more studies, especially prospective studies, are needed to validate our results.
胰腺癌是预后最差的恶性肿瘤之一。幽门螺杆菌已被确认为 I 类致癌原。已有多项研究评估了幽门螺杆菌感染与胰腺癌发展之间的关系,但结论并不一致。
在 PubMed、EMBASE、Cochrane 图书馆和中国知网数据库中进行文献检索,以确定符合条件的研究。我们对所有纳入的研究进行了总体荟萃分析,并根据地域分布进行了亚组分析。考虑了研究的质量(使用纽卡斯尔-渥太华质量评估量表对病例对照研究进行评估)和幽门螺杆菌的 CagA+菌株,并分别进行了包括高质量研究和 CagA+幽门螺杆菌研究的额外分析。
纳入了 9 项研究,共涉及 3033 名受试者(1083 例胰腺癌病例,1950 例对照)。对所有纳入研究的总体荟萃分析的汇总 OR 和 95%CI 为 1.47 和 1.22-1.77,4 项高质量研究的汇总数据为 OR 1.28,95%CI 为 1.01-1.63。检测 CagA+菌株的 5 项研究的 OR 为 1.42,相应的 95%CI 为 0.79 至 2.57。基于地域分布的亚组分析的汇总估计值如下,欧洲组:OR 1.56,95%CI 1.15-2.10;东亚组:OR 2.01,95%CI 1.33-3.02;北美组:OR 1.17,95%CI 0.87-1.58。9 项研究之间无明显异质性。未发现发表偏倚。
幽门螺杆菌感染与胰腺癌的发生显著相关,但相关性较弱。这种相关性在欧洲和东亚更为明显,但在北美不明显。CagA+幽门螺杆菌菌株似乎与胰腺癌无关。然而,需要更多的研究,特别是前瞻性研究,来验证我们的结果。